Summary:
A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of amg 334 in migraine prevention.
Qualified Participants Must:
• Be between 18 and 60 years of age
•
Have a history of migraines for at least 12 months
•
Have at least 4 and no greater than 14 migraine days per month
Qualified Participants May Receive:
Study Medication and travel Stipend.